Do Medicare's Facility Fees Incentivize Hospitals to Vertically Integrate with Oncologists?

analysis of health care markets facility fees health economics medicare vertical integration

Journal

Inquiry : a journal of medical care organization, provision and financing
ISSN: 1945-7243
Titre abrégé: Inquiry
Pays: United States
ID NLM: 0171671

Informations de publication

Date de publication:
Historique:
entrez: 16 7 2021
pubmed: 17 7 2021
medline: 16 10 2021
Statut: ppublish

Résumé

Within the past decade, the U.S. health care market has undergone massive vertical integration, prompting economists to study the underlying causes and consequences of hospital-physician integration. This paper examines whether or not hospitals strategically choose to vertically integrate with clinical oncologists in order to capture facility fees, a commonly cited reason for increased consolidation in the health care market. To address this question, I match data on hospitals' ownership of clinical oncologists with Medicare payment data disaggregated to the physician and specific service level. I leverage a 2014 policy change that drastically altered the payment structure of Medicare's facility fees paid to hospitals for evaluation and management services-and yet, it did not alter the direct payments made to physicians. Contrary to popular belief, I find no evidence that the financial incentives of facility fees have an effect on the probability that a hospital and a clinical oncologist vertically integrate.

Identifiants

pubmed: 34269086
doi: 10.1177/00469580211022968
pmc: PMC8287339
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

469580211022968

Subventions

Organisme : AHRQ HHS
ID : T32 HS000046
Pays : United States

Références

Med Care Res Rev. 2021 May 24;:10775587211013628
pubmed: 34027744
J Health Econ. 2017 Mar;52:19-32
pubmed: 28182998
J Health Econ. 2006 Jan;25(1):175-80
pubmed: 16318890
Health Aff (Millwood). 2017 Apr 1;36(4):680-688
pubmed: 28373334
J Health Econ. 2018 May;59:139-152
pubmed: 29727744
J Gen Intern Med. 2015 Aug;30 Suppl 3:S595-601
pubmed: 26105676
Health Aff (Millwood). 2014 May;33(5):756-63
pubmed: 24799571
Health Serv Res. 2013 Apr;48(2 Pt 2):696-712
pubmed: 23347041
N Engl J Med. 2018 Feb 08;378(6):539-548
pubmed: 29365282
MGMA Connex. 2012 Nov-Dec;12(10):17-9
pubmed: 23342724
Health Aff (Millwood). 2017 Feb 1;36(2):346-354
pubmed: 28167725
Health Aff (Millwood). 2018 Jul;37(7):1123-1127
pubmed: 29985694
J Health Econ. 2016 Dec;50:1-8
pubmed: 27639202

Auteurs

Samuel Valdez (S)

University of California, Los Angeles, CA, USA.
University of Southern California, Los Angeles, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH